Alpha Teknova, Inc. (TKNO)

Alpha Teknova is a supplier of reagents and biochemical products that power the discovery and manufacturing of therapeutics, vaccines, and diagnostic tools used worldwide. The company operates in a critical but unglamorous corner of the life sciences ecosystem: it provides the culture media, buffers, and molecular biology reagents that researchers and manufacturers depend on to grow cells, develop drugs, and scale production from laboratory benches to commercial manufacturing facilities. For every breakthrough drug or vaccine that reaches the market, dozens of smaller companies like Alpha Teknova work behind the scenes, earning recurring revenue by providing the consumables and media that the process cannot happen without.

Founded in 1996 and based in Hollister, California, Alpha Teknova sold shares to the public in 2021. The company sells to pharmaceutical companies, biotechnology firms, contract development and manufacturing organisations (CDMOs), academic institutions, and diagnostic companies—essentially anyone doing serious work in the life sciences. Its products are commodities in the sense that they are not differentiated by brand (customers choose by performance and reliability, not marketing), yet they are sticky in practice: once a protocol is validated with a particular reagent, switching to a competitor’s equivalent is friction-filled and risky. That stickiness, combined with the recurring nature of consumable purchases, creates a durable business model.

“The reagent supply chain is invisible to patients but essential to every drug and vaccine.”

The life sciences industry has structured itself into layers. At the top are the major pharmaceutical companies and the splashy biotechs that discover and commercialize drugs. Beneath them are specialist suppliers—contract manufacturers, testing labs, and reagent makers—who provide the enabling infrastructure. Alpha Teknova occupies that supplier layer, a position that has advantages and constraints. The advantage is recurring revenue: customers buy consumables perpetually, not just once. The constraint is that the major pharma and biotech companies have substantial bargaining power, and margins depend on manufacturing efficiency and scale. Alpha Teknova’s growth is therefore closely tied to the health of the life sciences sector overall and the budgets of its largest customers.

What Alpha Teknova makes and sells

The company’s product portfolio is organised around three main lines. Lab Essentials consists of pre-poured culture media plates, liquid microbial media supplements, and molecular biology reagents. These are the foundational tools for growing cells and bacteria, cloning DNA, and manipulating genetic material. Researchers order these in bulk and consume them in their daily work. Clinical Solutions is a newer, higher-value line of custom or semi-custom formulations designed specifically for the development and manufacturing of protein therapies (such as monoclonal antibodies), gene therapies, mRNA vaccines, and diagnostic assays. This segment commands higher margins because each formulation is tailored to a customer’s specific needs, and switching costs are higher. Contract Manufacturing and Services involves custom formulation work and small-scale manufacturing for customers who need bespoke media or reagent batches.

The composition of revenue across these lines reflects the long-term shift in the life sciences industry toward biologics and therapies made from living cells or genetic material. Twenty years ago, the typical small-molecule drug was synthesised in a chemical reactor, and reagent suppliers served a more chemistry-focused customer base. Today, the industry is awash in cell-based and genetic therapies, each requiring specialised growth media and reagents. Alpha Teknova has benefited from this structural shift. Clinical Solutions revenue has grown faster than the legacy lab-essentials business, which means the company is moving toward higher-margin, more-differentiated products.

The unit economics of consumables

Alpha Teknova’s business model rests on three pillars. First, the company manufactures or sources its products at relatively low cost and sells them at a markup, typically capturing gross margins in the range of 60–70%, which is strong for a manufacturing business. Second, once a customer adopts a product and integrates it into a research or manufacturing protocol, the customer tends to reorder the same item repeatedly, sometimes for years. This reduces the company’s need to spend heavily on marketing to acquire new customers—existing customers generate recurring revenue with minimal incremental cost. Third, the life sciences sector itself is secular-growth, driven by ageing populations, chronic disease, and the rise of genetic medicine. Budget cuts and downturns happen, but the long-term trajectory favours suppliers to the industry.

The risk embedded in this model is that Alpha Teknova has no direct control over its end-market. The company’s revenue is ultimately a function of how much money customers—pharma companies, biotechs, and CDMOs—spend on research and development and manufacturing. When venture capital funding to biotech dries up, when large pharma companies cut R&D budgets, or when a manufacturing cycle slows, Alpha Teknova’s customers cut their consumable orders. The company also faces competition from larger, diversified life-sciences suppliers such as Thermo Fisher and Merck KGaA (Sigma-Aldrich), which can bundle reagents with other products and use their scale to undercut smaller rivals. Alpha Teknova’s advantage is focus and customisation—it is more agile than the giants—but scale and breadth will always remain competitive weapons.

Growth drivers and sector tailwinds

Alpha Teknova’s growth is propelled by the expansion of the biologics industry and the increasing sophistication of therapies. The mRNA vaccine platforms that emerged during the COVID-19 pandemic created entire new classes of customers needing specialised reagents and media. Gene therapy and cell therapy are growing rapidly, each requiring novel culture systems and supporting reagents. Contract manufacturers are proliferating as large pharma companies outsource non-core manufacturing, and each new CDMO is a potential Alpha Teknova customer. The customisation and clinical-solutions segment is particularly well positioned to capture this trend because customers developing cutting-edge therapies need tailored formulations that mass-market reagent suppliers cannot easily provide.

Conversely, the company faces cyclical pressures. Biotech funding booms attract new companies and fund expansions, which drives consumable purchases. Biotech funding droughts force companies to conserve cash and reduce spending, which hits suppliers like Alpha Teknova immediately. The company also remains vulnerable to consolidation: if two large pharmaceutical companies merge, they may standardise on different suppliers, cutting orders from some and consolidating business with others.

How to research Alpha Teknova

A reader interested in Alpha Teknova should start with the company’s annual 10-K filing with the SEC (CIK 0001850902), which details the customer base (often anonymised but sometimes broken down by sector), product revenue by line, gross margins, and management’s assessment of growth drivers. The quarterly earnings calls and transcripts reveal management commentary on which customer segments are spending and which are pulling back, and offer colour on the state of biotech funding and manufacturing activity. Watch the clinical-solutions segment closely, as it is the faster-growing, higher-margin business and a signal of whether the company is successfully moving upmarket. Monitor gross margin trends for signs of pricing pressure or manufacturing inefficiency. Pay attention to customer concentration: if a small number of customers account for a large share of revenue, the loss of one is a material risk. Finally, track the broader life sciences equipment and consumables indices to gauge whether demand from the sector is accelerating or decelerating. Alpha Teknova’s stock tends to move with the health of biotech and pharma spending, not in isolation.